-
1.发明申请公开(公告)号：US20190389948A1
公开(公告)日：2019-12-26
申请号：US16407848
申请日：2019-05-09
Inventor： Rifaat SAFADI
Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
-
2.发明申请MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 有权NLGn4表达的调节，非酒精性脂肪肝疾病（NAFLD）中的NK细胞活性公开(公告)号：US20160115485A1
公开(公告)日：2016-04-28
申请号：US14963319
申请日：2015-12-09
Inventor： Rifaat SAFADI
IPC: C12N15/113
CPC classification number: C12Q1/6883 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q2600/158
Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
Abstract translation: 本发明提供通过抑制NGn4表达从而调节NK细胞的活性来治疗，减轻或预防肝脏疾病的方法。 本发明还涉及通过评估NK细胞中的NLGn4表达来诊断肝脏疾病。
-
Patent Agency Ranking
公开(公告)号：US20220010009A1
公开(公告)日：2022-01-13
申请号：US17388218
申请日：2021-07-29
Inventor： Rifaat SAFADI
Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
-
4.发明申请MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 有权NLGn4表达的调节，非酒精性脂肪肝疾病（NAFLD）中的NK细胞活性公开(公告)号：US20160369347A1
公开(公告)日：2016-12-22
申请号：US15256781
申请日：2016-09-06
Inventor： Rifaat SAFADI
IPC: C12Q1/68 , A61K31/7088 , C12N15/113
CPC classification number: C12Q1/6883 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q2600/158
Abstract: The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an NLGn4 gene product in the immune cell population using NLGn4 specific primers or NLGn4 specific probes.
Abstract translation: 本发明提供了诊断和/或监测受试者中肝脏疾病的方法。 该方法要求从受试者的生物样品中分离免疫细胞群体; 并使用NLGn4特异性引物或NLGn4特异性探针检测免疫细胞群体中NLGn4基因产物的表达水平。
-
公开(公告)号：US20240409602A1
公开(公告)日：2024-12-12
申请号：US18812184
申请日：2024-08-22
Inventor： Rifaat SAFADI , Johnny AMER
IPC: C07K14/705 , A61K35/17 , A61K38/00 , A61P1/16 , A61P35/00 , C12N5/0783
Abstract: Provided herein are isolated peptides capable of affecting neuroligin-4 (NLGn4)-neurexin 1β (Nrx1β) protein-protein interaction and interfering with NLGn4X/Nrx1β axis between Hepatic Stellate Cells (HSCs) and Natural killer (NK). Further provided are compositions including such peptides and uses thereof for treating and/or attenuating liver-related conditions and various types of cancer.
-
6.发明申请公开(公告)号：US20180202001A1
公开(公告)日：2018-07-19
申请号：US15914112
申请日：2018-03-07
Inventor： Rifaat SAFADI
IPC: C12Q1/6883 , A61K31/713 , A61K31/7105 , C12N15/113 , A61K45/06 , A61K31/7088
CPC classification number: C12Q1/6883 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q2600/158
Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.
-
7.发明申请公开(公告)号：US20180111989A1
公开(公告)日：2018-04-26
申请号：US15562602
申请日：2016-03-31
Inventor： Rifaat SAFADI
CPC classification number: C07K16/28 , A61K38/16 , A61K38/1709 , A61K38/177 , A61K2039/505 , A61P1/16 , C07K2317/34 , C07K2317/52 , C07K2317/76 , C07K2319/30
Abstract: Provided is a method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction. Also provided are compositions including the agent.
-
-
-
-
-
-
Search Results
7
records
(took 0.019 seconds)
